GlaxoSmithKline

GSK announces Dr Gavin Screaton to join the Board as Non-Executive Director

21 Feb 2025

GSK plc has today announced that Dr Gavin Screaton has been appointed to the Board of the Company as a Non-Executive Director.

21 February 2025

21 Feb 2025

GSK plc has today announced that Dr Gavin Screaton has been appointed to the Board of the Company as a Non-Executive Director.

Nucala (mepolizumab) application for COPD accepted for review in China

20 Feb 2025

Around 100 million people live with COPD in China, accounting for almost 25% of all COPD cases globally

20 February 2025

20 Feb 2025

Around 100 million people live with COPD in China, accounting for almost 25% of all COPD cases globally

15 February 2025

15 Feb 2025

Vaccine helps protect against five common disease-causing serogroups of Neisseria meningitidis (A, B, C, W and Y).

Penmenvy, GSK’s 5-in-1 meningococcal vaccine, approved by US FDA to help protect against MenABCWY

15 Feb 2025

Vaccine helps protect against five common disease-causing serogroups of Neisseria meningitidis (A, B, C, W and Y).

GSK delivers strong 2024 performance with further improvement to long-term growth outlook

05 Feb 2025

Q4 and full year 2024 performance highlights

05 February 2025

05 Feb 2025

Q4 and full year 2024 performance highlights

31 January 2025

31 Jan 2025

Vocabria + Rekambys (cabotegravir + rilpivirine) is the first and only complete long-acting injectable for the treatment of HIV.

European Commission authorises ViiV Healthcare’s long-acting injectable Vocabria + Rekambys for HIV treatment in adolescents

31 Jan 2025

Vocabria + Rekambys (cabotegravir + rilpivirine) is the first and only complete long-acting injectable for the treatment of HIV.

View details about the software product Informachine News Trackers